NCT00335335

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

Phase 3, Open-label, Multicenter Studies to Determine Efficacy and Safety of VISIPAQUETM (Iodixanol) Injection for Use in Intravenous Contrast-Enhanced CT Angiography of Coronary Arteries

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 89 (actual)
• Sponsor: GE Healthcare · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

CT (computed tomography) angiography (CTA) is an examination similar to a CAT scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body. VISIPAQUE™ will be given through a vein in the arm before having the CTA scan of the heart arteries. The pictures it produces of the heart and its blood vessels will be reviewed and compared to those obtained during the catheter-based coronary angiography to see if the CTA shows the same blockages.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	iodixanol

Timeline

• Start date: 2006-05-01
• Primary completion: 2006-12-02
• Completion: 2006-12-02
• First posted: 2006-06-09
• Last updated: 2019-04-25

Locations

1 site across 1 country: United States